Search

FUS1 is a tumor suppressor gene that has been found to be frequently lost in a variety of solid tumors. In this study, we aimed to investigate the expression status of the FUS1 gene in acute myeloid leukemia (AML), as well as its clinical significance. We further explored the correlation between the expression of FUS1 and miR-378 in AML. We detected expression of the FUS1 transcript in bone marrow mononuclear cells from 23 controls and 158 newly diagnosed AML patients by real-time quantitative polymerase chain reaction. Downregulated FUS1 expression was found in 139 out of 158 (87.97%) AML cases; this rate was significantly lower than that in all 23 controls (p = 0.012). Receiver operating characteristic curve analysis revealed that the FUS1 transcript level could discriminate AML patients from controls effectively (area under the ROC curve = 0.663). Kaplan-Meier analysis demonstrated that non-M3-AML patients with a low FUS1 expression had a shorter overall survival (p = 0.049) and leukemia-free survival (p = 0.051) than those with a high FUS1 expression. Furthermore, we studied the correlation between the expression of FUS1 and miR-378 in 53 newly diagnosed AML patients. We found that the correlation coefficient was –0.346, which showed that FUS1 and miR-378 were negatively correlated in AML patients (p = 0.011). These results indicate that the low expression of FUS1 is a common molecular event in AML.

Chemerin is dysregulation in numerous solid cancers. However, only little is known about the role of chemerin in acute myeloid leukemia (AML). In this study, we aimed to investigate the expression and clinical significance of recently described chemerin in acute myeloid leukemia (AML). The expression of chemerin in 149 patients with de novo AML and 35 normal controls was quantified by Real-time quantitative PCR (RQ-PCR). Chemerin was down-expressed in AML compared with controls (P=0.042). A receiver operating characteristic (ROC) curve revealed that chemerin expression could differentiate patients with AML from control subjects (AUC=0.611, 95% CI: 0.490-0.732; P=0.042) respectively. The cohort of AML patients was divided into two groups according to the cut-off value of 0.0826 (79% sensitivity and 54% specificity, respectively). In addition, the AML patients with low chemerin expression had significantly shorter overall survival (OS) than those with high chemerin expression (P=0.049). Moreover, multivariate survival analysis confirmed that chemerin was an independent prognostic factor for AML patients. In conclusion, downregulation of chemerin might be a useful diagnostic and prognostic factor for AML patients.

This study was intended to investigate the expression status of Vimentin 2p (VIM 2p), a pseudogene of Vimentin, and further analyze its clinical significance in AML patients.Real-time quantitative PCR (RQ-PCR) was employed to explore the expression status of VIM 2p in 128 patients with de novo AML and 36 healthy controls.The expression level of VIM 2p was significantly decreased compared with healthy controls (P0.001). The patients with low VIM 2p expression were identified in 93 of 128 (73%) of AML patients. No significant differences could be observed in sex, age, blood parameters, FAB/WHO subtypes, karyotype risks and ten gene mutations (FLT3-ITD, NPM1, C-KIT, IDH1/IDH2, DNMT3 A, C/EBPA, N/K-RAS and U2AF1) between VIM 2p low-expressed and high-expressed patients (P0.05). Patients with low VIM 2p expression had significantly shorter overall survival (OS) than those with high VIM 2p expression in whole AML cases (median 7 vs. 13 months, respectively, P= 0.032), besides cytogenetically normal AML (CN-AML) and non-M3 AML cohort (P= 0.042 and 0.045, respectively).These findings indicate that VIM 2p down-regulation is a common event in AML and may be associated with poor clinical outcome.

In recent years, many researches have shown that OCT4 is overexpressed in both germ cell tumors and somatic cancers. Meanwhile, OCT4 has relationship with poor prognosis in a lot of solid tumors, such as hepatocellular carcinoma, gastric cancer, and esophageal cancer. In our study, we investigated the expression status of OCT4 and its clinical significance in patients with acute myeloid leukemia (AML) using real-time quantitative PCR. The receiver operating characteristic (ROC) curve reveals that the level of OCT4 expression could be available for a potential diagnostic biomarker for differentiating AML from controls with an area under the ROC curve (AUC) of 0.915 (95 % confidence interval (CI) 0.837-0.992; P 0.001). At the cutoff value of 0.56, the sensitivity and the specificity are 75.9 and 81.2 %, respectively. The amount of white blood cell (WBC) of patients with high OCT4 expression is higher than that of patients with low OCT4 expression (18.2 × 10(9) versus 2.7 × 10(9) L(-1), P = 0.001). Among those patients who are less than 70 years old, patients with OCT4 high expression have significantly shorter overall survival (OS) than those without OCT4 high expression (P = 0.048). These findings suggest that OCT4 high expression is a common event and may have an adverse impact on prognosis in AML.

FUS1 is a tumor suppressor gene that has been found to be frequently lost in a variety of solid tumors. In this study, we aimed to investigate the expression status of the FUS1 gene in acute myeloid leukemia (AML), as well as its clinical significance. We further explored the correlation between the expression of FUS1 and miR-378 in AML. We detected expression of the FUS1 transcript in bone marrow mononuclear cells from 23 controls and 158 newly diagnosed AML patients by real-time quantitative polymerase chain reaction. Downregulated FUS1 expression was found in 139 out of 158 (87.97%) AML cases; this rate was significantly lower than that in all 23 controls (p = 0.012). Receiver operating characteristic curve analysis revealed that the FUS1 transcript level could discriminate AML patients from controls effectively (area under the ROC curve = 0.663). Kaplan-Meier analysis demonstrated that non-M3-AML patients with a low FUS1 expression had a shorter overall survival (p = 0.049) and leukemia-free survival (p = 0.051) than those with a high FUS1 expression. Furthermore, we studied the correlation between the expression of FUS1 and miR-378 in 53 newly diagnosed AML patients. We found that the correlation coefficient was -0.346, which showed that FUS1 and miR-378 were negatively correlated in AML patients (p = 0.011). These results indicate that the low expression of FUS1 is a common molecular event in AML.

Four new Ni(II) complexes [Ni(L)(SO4)(H2O)2]·H2O (1), [Ni3(L)4(p-BDC)3(H2O)6]·6H2O (2), [Ni(L)(m-BDC)(H2O)2]·0.5H2O (3) and [Ni(L)(BPDC)(H2O)2] (4) have been prepared by reactions of 3,5-di(1H-benzimidazol-1-yl)pyridine (L) with nickel sulfate in the presence of auxiliary ligands of phthalic acid (o-H2BDC), terephthalic acid (p-H2BDC), isophthalic acid (m-H2BDC) and biphenyl-4,4′-dicarboxylic acid (H2BPDC), respectively. Interestingly, phthalate (o-BDC2−) did not take part in formation of 1, instead SO 4 2 - was found in 1. Complex 2 with p-BDC2− shows different two-dimensional (2D) network from 1 while 3 has one-dimensional (1D) chain structure. Complex 4 is a three-dimensional (3D) framework with CdSO4 topology. The thermal stability and adsorption property of the complexes were investigated. Furthermore, it was found that complexes 1–4 can catalyze acetalization reaction of aldehydes with methanol, and 1 gives the highest yield.

Accumulating evidences indicate that bisphenol A (BPA) exposure during early development increases the risk of obesity and insulin resistance in later life. Despite growing public concern, it is not totally clear about the mechanism of BPA. This study aimed to evaluate the effect of perinatal exposure to BPA on body weight, glucose metabolism and adipokine expression in adolescent female offspring rats. Pregnant rats were exposed to BPA in water at levels of either 1 μg/mL (LBPA) or 10 μg/mL (HBPA) from gestation day 6 to the end of lactation. Body weight, the levels of fasting serum glucose, insulin and adiponectin (ADP), and Zinc-alpha2-glycoprotein (ZAG) and ADP mRNA and protein expression from adipose tissue in 7 weeks old female offspring were measured. There were high birth weight and high body weight at age of 7 weeks in BPA treated group. There were significantly higher levels of serum glucose and insulin, and lower levels of serum ADP and plasma ZAG protein, and lower ADP and ZAG mRNA and protein expression in BPA-exposed female offspring compared with controls. The results suggested that BPA-exposed during early development had long-term deleterious effects on body weight and glucose metabolism, which was probably associated with the down-regulated expression of ZAG and ADP gene in early developmental female rats.

The BMI1P1 levels of 144 de novo AML patients and 36 healthy donors were detected by real-time quantitative PCR (RQ-PCR). BMI1P1 was significantly down-regulated in AML compared with control (P < 0.001). A receiver operating characteristic (ROC) curve revealed that BMI1P1 expression could differentiate patients with AML from control subjects (AUC = 0.895, 95% CI: 0.835-0.954, P < 0.001). The percentage of blasts in bone marrow (BM) was significantly lower in BMI1P1 high-expressed group versus low-expressed group (P = 0.008). BMI1P1 high-expressed cases had significantly higher complete remission (CR) than BMI1P1 low-expressed cases (P = 0.023). Furthermore, Kaplan-Meier demonstrated that both whole AML cohort and non-M3-AML patients with low BMI1P1 expression showed shorter leukemia free survival (LFS, P = 0.002 and P = 0.01, respectively) and overall survival (OS, P < 0.001 and P = 0.011, respectively) than those with high BMI1P1 expression. Multivariate analysis also showed that BMI1P1 over-expression was an independent favorable prognostic factor for OS in both whole and non-M3 cohort of AML patients (HR = 0.462, 95% CI = 0.243-0.879, P = 0.019 and HR = 0.483, 95% CI = 0.254-0.919, P = 0.027). To further investigate the significance of BMI1P1 expression in the follow-up of AML patients, we monitored the BMI1P1 level in 26 de novo AML patients and found that the BMI1P1 level increased significantly from the initial diagnosis to post-CR (P < 0.001). These results indicated that BMI1P1 might contribute to the diagnosis of AML and the assessment of therapeutic effect.

Five new coordination complexes, namely [Ag(L)](BF 4 ) ( 1 ), [Ag 6 (L) 4 (NO 3 ) 6 ] ( 2 ), [Ag 3 (L) 4 (CH 3 CN) 2 ](SbF 6 ) 3 (H 2 O) ( 3 ), [Ag(L)(OOCCF 3 )] ( 4 ) and [Ag(L)(CH 3 SO 3 )] ( 5 ), have been obtained by the reactions of the ligand 4-(2-oxazolinyl)pyridine (L) with different Ag(I) salts under the same reaction conditions. The frameworks of 1 – 5 show different structural features: complex 1 is a zigzag chain; complexes 2 – 4 contain 2D networks with different topologies; complex 5 , interestingly, contains both a zigzag chain and a 2D network. The results reveal that the nature of the counteranions, such as their shape and size, coordination ability and coordination mode, has a great effect on determining the resulting structures. Meanwhile, electrospray mass spectrometry (ES-MS) shows the existence of the fragment of a coordination polymer in the solution.

Six new coordination complexes [Ag2(L)2](NO3)2 (1), [Ag2(L)2](ClO4)2 (2), [Ag3(L)4](SbF6)3 (3), [Ag2(L)2(CH3CN)2](PF6)2 (4), [Ag2(L)2(SO3CH3)2](CH3OH)2 (5) and [Ag2(L)2(SO3CF3)2] (6) were successfully synthesized by reactions of 1,3-bis(2-oxazolinyl)benzene (L) with different Ag(I) salts under the same reaction conditions. Complexes 1 and 2 have the same 16-membered ring structures, which are extended by Ag···O weak interactions and hydrogen bonds to form 3D frameworks. Complex 3 containing two- and four-coordinated Ag(I) atoms has two inter-connected 16-membered rings which are linked together by SbF 6 - to form a 3D framework. In complex 4, the Ag(I) is three-coordinated by two N atoms from the L ligands and one N atom from acetonitrile solvent and the structure of 4 is also a 16-membered ring. Complexes 5 and 6 have similar 16-member ring structure, and the anions coordinate with Ag(I) atoms. The results reveal that anions can influence on the structure of the complexes. Furthermore, the complexes were characterized by electrospray mass spectrometry.

Three new silver(I) complexes, [Ag2(L)3](BF4)2 (1), [Ag2(L)3](PF6)2 (2), and [Ag2(L)(CF3COO)2] (3), have been synthesized by reactions of 1,4-bis(2-oxazolinyl)benzene (L) with the corresponding silver(I) salt. The complexes were characterized by elemental analysis, IR, electrospray mass spectrometry, thermogravimetric analyses, powder X-ray diffraction, and single-crystal X-ray diffraction. The crystal structure analyses reveal that 1 and 2 crystallize in the same monoclinic space group P21/c and have the same 2-D layer structure, in which the counteranions and do not coordinate with silver(I). For 3, CF3COO− are auxiliary linkers to connect silver(I)'s to give 1-D chains which are further connected by L to form a 2-D layer structure. The results revealed that the nature of counteranions have impact on the structure of complexes.

The purpose of this study was to investigate the expression status of Dual-Specificity Phosphatase 5 Pseudogene 1 (DUSP5P1) and its clinical relevance in patients with acute myeloid leukemia (AML). Real-time quantitative PCR (RQ-PCR) was performed to detect the status of DUSP5P1 expression in 89 patients with de novo AML and 24 normal controls. The level of DUSP5P1 expression was significantly up-regulated in AML compared to controls (P=0.031). The patients with high expression of DUSP5P1 had higher percentage of blasts in bone marrow (BM) than those without high expression (P=0.027). The occurrence rate of DUSP5P1 high expression was significantly higher in M1 (2/8, 25%) and M2 subtypes (9/33, 27%) than in M3 subtype (0/17, 0%) (P=0.034). At the same time, the frequency of DUSP5P1 high expression in patients with intermediate (13/53, 24%) and poor karyotypes (5/11, 45%) was significantly higher than that in patients with favorable karyotype (0/21, 0%) (P=0.003). Meanwhile, DUSP5P1 high-expressed patients had significantly shorter overall survival (OS) than those with low expression (median 4.5 vs. 10.5 months, respectively, P=0.038). Our findings indicated that high expression of DUSP5P1 may identify high-risk AML patients and is associated with poor prognosis in AML.

An economic, efficient and green silver oxide nanoparticle catalyzed three-component coupling reaction of aldehydes, amines and alkynes was developed. This method provided various propargylamines in moderate to high yield at room temperature in air. The silver oxide nanoparticles could be separated simply and reused without significant decrease of activity.

The research and development of the KTP crystal with high threshold is of very importance for its application in high-energy laser systems. Ablation characteristics in KTP crystal as well as their influence on the Raman spectroscopy were studied by UV laser with high repetition frequency. The research results show that the laser plasma effects are the main reasons for the damage in the KTP crystal. The inverse bremsstrahlung absorption effect can increase the deposition of the laser pulse energy greatly; the ionization effect can make the crystal dislocated completely; shock wave effect can push away the mixture of melted, vaporized and ionized materials and cause cracks in the pit. Through investigation and comparison of the Raman spectroscopy before and after the laser ablation, it was found that the distribution characteristics of Raman peaks are almost the same, suggesting that the basic structures of KTP crystal do not change. But almost all the Raman characteristic peaks' R1R values have changed and the widths are broadened, which means that the crystalline degree has been decreased. The Raman peaks of TiO6 and PO4 oxygen polyhedron shift to the lower wave number, which indicates that bonding force becomes weaker and the KTP crystal can be damaged easily.

To study the leptin receptor isoforms regulation by leptin and insulin.Human hepatocellular carcinoma cells of the line HepG2 were cultured in DMEM containing 10% FBS in six-well plate and were incubated for 24 hours in serum-free medium containing 0, 10(-9), 10(-8), 10(-7), and 10(-6) mol/L of human leptin or insulin. Using the semi-quantitative RT-PCR technique, the mRNA expressions of long (OB-Rb) and short (OB-Ra: OB-R219.3) leptin receptor isoforms were measured.OB-Rb and OB-R219.3 mRNAs were expressed in this cell line. Leptin of the concentrations of 10(-7) approximately 10(-6) mol/L significantly inhibited the OB-Rb mRNA expression, with the maximum decrease (by 43%) at the concentration of 10(-6) mol/L. Similarly the mRNA expression of OB-R219.3 was also markedly reduced in cells treated with leptin of the concentrations of 10(-8) approximately 10(-6) (mol/L), with the maximum inhibition (by 49%) at the concentrations of 10(-6) mol/L. Insulin showed no effect on OB-Rb and OB-R219.3 mRNAs expression in HepG2 cell.In HepG2 cells, leptin down-regulates the expressions of OB-Rb and OB-R219.3 mRNAs, and insulin has no effect on OB-Rb and OB-R219.3 mRNAs, which contributes at least partly to an understanding of the mechanism of leptin resistance in vivo and suggests that leptin-induced receptor down-regulation may be relevant to leptin resistance at sites of peripheral action.